Molecular and functional study of somatostatin receptors in pheochromocytomas and paragangliomas

#3257

Introduction: Most pheochromocytomas (PCC) and paragangliomas (PGL) are benign neuroendocrine tumors that overproduce catecholamines causing hypertension, arrhythmia, and stroke; however, 10 30% may present distant metastasis. About 40% are caused by germline mutations, which may be classified in 3 different clusters. PCC/PGL diagnosis involves blood/urine tests and imaging techniques, while their treatment often requires distinct pharmacological and surgical approaches. Thus, identification of new biomarkers for early diagnosis, and progression/response would help to avoid unnecessary tests and enable personalized medicine approaches.

Aim(s): Somatostatin receptors (SST1-5) are used as diagnostic tools or therapeutic targets in endocrine-related tumors. The objective of this work is to assess their presence and potential clinical value in PCC and PGL.

Materials and methods: Somatostatin system was evaluated in fresh tissues derived from three cohorts (Marseille, Madrid, and Córdoba) comprising 67 PCC and 28 PGL, and an online database of 144 PCC and 29 PGL (TCGA). In vitro studies were performed on primary cultures and PC12 cell line.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Ibáñez-Costa A

Authors: Ibáñez-Costa A, Blázquez-Encinas R, Alors-Pérez E, Fuentes-Fayos A, Rivero-Cortés E,

Keywords: pheochromocytoma, paraganglioma, somatostatin, somatostatin receptor, neuroendocrine tumor,